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Abstract
Background: The number of breast cancer patients diagnosed with ductal carcinoma in situ
(DCIS) continues to grow. Laboratory and clinical data indicate that DCIS can progress to invasive
disease. Carbohydrate-mediated cell-cell adhesion and tumor-stroma interaction play crucial roles
in tumorigenesis and tumor aggressive behavior. Breast carcinogenesis may reflect quantitative as
well as qualitative changes in oligosaccharide expression, which may provide a useful tool for early
detection of breast cancer. Because tumor-associated carbohydrate antigens (TACA) are
implicated in tumor invasion and metastasis, the purpose of this study was to assess the expression
of selected TACA by lectin histochemistry on DCIS specimens from the archival breast cancer
tissue array bank of the University of Arkansas for Medical Sciences.
Methods: For detection of TACA expression, specimens were stained with Griffonia simplicifolia
lectin-I (GS-I) and Vicia vilosa agglutinin (VVA). We studied associations of lectin reactivity with
established prognostic factors, such as tumor size, tumor nuclear grade, and expression of Her-2/
neu, p53 mutant and estrogen and progesterone receptors.
Results: We observed that both lectins showed significant associations with nuclear grade of
DCIS. DCIS specimens with nuclear grades II and III showed significantly more intense reactivity
than DCIS cases with nuclear grade I to GS-1 (Mean-score chi-square = 17.60, DF = 2; P = 0.0002)
and VVA (Mean-score chi-square = 15.72, DF = 2; P = 0.0004).
Conclusion: The results suggest that the expression of VVA- and GS-I-reactive carbohydrate
antigens may contribute to forming higher grade DCIS and increase the recurrence risk.
Background
Breast carcinoma is the most common malignancy and
currently the second leading cause of cancer death in
women in the United States. An increasing number of
women choose more sensitive screening with digital
mammograms and magnetic resonance imaging, which
has ultimately resulted in dramatic increase in the diagno-
sis of ductal carcinoma in situ (DCIS) during recent years
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[1-4]. The majority of invasive breast cancers likely
develop over extended periods of time from pre-invasive
lesions such as DCIS and culminating in metastatic dis-
ease [5-9]. Untreated DCIS lesions develop into invasive
breast cancer with an average progression rate of 43% as
estimated by using the results of 8 different independent
studies performed with a wide range of follow-up time
[3].
An increased risk of a recurrence as DCIS or invasive can-
cer was associated with initial DCIS lesions that were
larger than 10 mm or were of high or intermediate nuclear
grade [10-14]. High nuclear grade of initial lesions and
cancer recurrence were significantly associated with
increased rates of metastasis and breast cancer death
[15,16]. Therefore, nuclear grade is used as a major deter-
minant of therapy and medical treatment decision for
DCIS patients [11,17,18].
Tumor initiation and growth is associated with modifica-
tions to the structure of glycan residues belonging to glyc-
oproteins, glycolipids and proteoglycans present at the
cell surface [19]. Aberrant glycosylation, arising from dys-
function of glycosyltransferases and/or glycosidases, most
often results in a shortening of the glycan chains or an
over-expression of structures on cells that are normally
absent or scarce. It is well-recognized that aberrant carbo-
hydrate expression is relevant to tumor metastasis and
poor prognosis for cancer patients [20-22].
A feature of adenocarcinoma cells is their high accumula-
tion of an abnormal mucin carbohydrate-substitution
pattern compared with mucin of normal epithelial cells.
This phenomenon is observed in most types of human
cancers including breast cancer [23-26]. The accumula-
tion of carbohydrate structures reactive with Vicia vilosa
agglutinin (VVA) and Griffonia simplicifolia lectin-I (GS-I)
is closely associated with development, progression, and
metastasis of breast adenocarcinoma [27-30]. VVA reacts
with N-acetyl-galactosamine (GalNAc) residues of glyco-
proteins that are predominantly expressed on the mucin
MUC1 [29,31]. The expression of VVA-reactive epitopes
has been linked to lymphatic invasion and lymph node
metastasis in invasive breast cancer [30]. GS-I lectin is a
mixture of isolectins that bind to Galα1-3Gal and α-Gal-
NAc terminal groups, which are involved in the formation
of metastases in murine and human breast carcinomas
[32-35].
Because the expression of cell surface carbohydrate struc-
tures reactive with VVA and GS-I lectins has been linked to
invasive breast cancer and its metastatic potential, we
hypothesized that the expression of TACA reactive with
these two lectins may define an aggressive phenotype in
DCIS. Therefore, the aim of this study was to assess the
expression of breast-cancer-related TACA markers reactive
with GS-I and VVA lectins in DCIS cases in order to evalu-
ate their presence and determine their correlations with
established tumor prognostic factors.
Methods
Study design
This retrospective study was conducted on archival tissue-
array blocks from patients diagnosed with DCIS between
1990–2002 at the University of Arkansas for Medical Sci-
ences. This study was approved by the University of
Arkansas for Medical Sciences Institutional Review Board.
Follow up information was available on all patients rang-
ing from 5 to 16 years. Patients' age, race and tumor char-
acteristics including tumor nuclear grade and size were
obtained from the pathology data base whenever possi-
ble. For the majority of cases immunohistochemistry
results of the molecular markers Her-2/neu, p53 and the
estrogen and progesterone receptors were also available in
pathology files. For the majority of the cases, immunohis-
tochemistry results of the molecular markers Her-2/neu,
p53 and the estrogen and progesterone receptors were
also available in the pathology files. Immunohistochemi-
cal studies for estrogen, progesterone and p53 were per-
formed on the original blocks using antibodies from
Ventana Medical Systems Inc. (Tucson, AZ). Anti ER clone
6F1, anti PR clone1A6 and anti-p53 clone Bp53-11 were
used. Any tumor with greater than 10% positivity with
estrogen and progesterone were recorded as positive. Any
nuclear positivity for p53 was reported as positive. Benign
breast tissue within the submitted sections was used as
internal positive control according to the pathology pro-
tocols. Hercept test by Dako (Carpinteria, CA) was used
for Her2-neu testing. The cases were scored according to
the DAKO standards of reporting for this antibody. The
tumor was reported as negative, if the tumor cells showed
no or weak incomplete cytoplasmic membrane staining.
They were reported as positive 2+, if the neoplastic cells
showed complete cytoplasmic membrane staining in
more than 10% tumor cells at weak or intermediate inten-
sity and positive (3+), if the tumor cells showed complete
strong cytoplasmic membrane staining. The pathologist
on record (SK) reviewed all samples and verified the pres-
ence of DCIS on the core used for the analysis. The study
conducted on total of 60 available DCIS cases.
Lectin histochemistry
Staining of tumor specimen with lectins was performed
based on a previously described method [36]. Briefly, for-
malin-fixed paraffin-embedded tissue were cut at four
microns and deparaffinized. Heat-induced epitope
retrieval was performed using 10× citrate buffer (Dako) in
a Fisher Isotemp water bath at 95–99°C. Slides were
cooled down for 20 minutes and rinsed in distilled water.BMC Cancer 2008, 8:136 http://www.biomedcentral.com/1471-2407/8/136
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Slides then were treated with PBS containing BSA (bovine
serum albumin, 20 mg in 10 ml PBS) for 20 minutes.
Slides were washed in PBS with added Calcium Chloride
(0.06 g to 1000 ml PBS) for 10 minutes with agitation.
Sections were then incubated with lectins (2 μg/ml, Vector
Laboratories, Burlingame, CA) for 30 min in PBS + 0.2%
BSA at room temperature (RT) and washed in PBS. Sec-
tions were then incubated with streptavidin-HRP (Vector
Laboratories) for 15 min at RT followed by PBS wash. Sec-
tions were incubated with diaminobenzidine solution
(DAB) for 5 min at RT, washed with distilled water, coun-
terstained with hematoxylin, mounted, and examined
under a light microscope. Cytospin slides of VVA and GS-
I-positive breast cancer cell line (MDA-MB-231) were used
for positive control. Stromal cells of the breast paren-
chyma did not show any positivity with either lectin.
These types of cells were present in all cores and were used
as negative internal control.
ELISA
ELISA was performed as described elsewhere [37]. Briefly,
plates were coated with 4 μg/ml of carbohydrate probes
attached to a polyacrylamide polymer (PAA) (GlycoTech
Corporation, Rockville, MA) in carbonate-bicarbonate
buffer at 4°C overnight. Biotinylated lectins were then
added and incubated for 1 hour at 37°C, and binding was
visualized with streptavidin-HRP (Sigma, St Louis, MO).
Absorbance was read, using a Bio-Tek ELISA reader (Bio-
Tek instruments, Inc, Highland Park, Vermont).
Scoring and statistical analysis
Tumor nuclear grade was determined using the Van Nuys
grading system [17,38]. The expression of carbohydrate
antigens was scored using a four-point staining-intensity
scale (from 0, negative; to 3+, strongly positive). The size
of initial tumor prior to 1999 was estimated based on the
available gross description and the archival slides. The
size, measured or estimated, was further categorized as 1
(≤ 1), 2 (> 1 and ≤ 2), 3 (> 2 and ≤ 3), 4 (> 3 and ≤ 4) and
5 (> 4). Association of staining intensities of lectins with
age, race, tumor size and grade, estrogen receptor (ER),
progesterone receptor (PR), p53, and Her-2/neu was char-
acterized using the Spearman coefficient of rank correla-
tion (rs). Associations between staining intensities and
other ordinal categorical variables were tested for statisti-
cal significance using the Mantel-Haenszel (MH) correla-
tion chi-square test [39]. Staining-intensity associations
with Age (the only continuous variable) were tested for
significance using the P values associated with the rank
correlations. The significance level for correlation analyses
was set at 0.5% alpha to adjust for the multiple compari-
sons without inflating Type II error. Staining-intensity
associations with nuclear grade of DCIS were further char-
actserized by computing for each grade the average stain-
ing-intensity score as follows: Average score = 0 ×
(proportion negative) + 1 × (proportion 1+) + 2 × (pro-
portion 2+) + 3 × (proportion 3+). Differences in average
scores between grades were tested for significance using
the extended Mantel-Haenszel mean-scores chi-square
test [39]. Recurrence-free survival (RFS) was also exam-
ined in grade I DCIS patients. RFS was measured from the
year of diagnosis to the year of recurrence, or censored at
last follow-up (2007) if no recurrence occurred by the end
of the year; the one death in 1999 for unrelated cause was
censored at death for competing risks. For association
with RFS, staining intensities were dichotomized as nega-
tive (0) versus positive (1+ or higher), and assessed for sig-
nificance using the log-rank test. Statistical analyses were
conducted using SAS Version 9.1.3 (The SAS Institute,
Cary, NC, USA).
Results
Patient population and tumor characteristics
Table 1 summarizes tumor size, nuclear grade, expression
levels of ER, PR, p53 and Her-2/neu, and age and race of
the breast cancer patients whose tumors were analyzed in
the present study. The distribution among subclasses in
each category is shown. African American women repre-
sented 25% of the patient population. The age of patients
Table 1: Characteristics of patients and tumors used for this 
study
Factor Category Number Percentage
Tumor size (cm) ≤ 11 3 2 1 . 7
> 1, ≤ 42 3 3 8 . 3
> 4 11 18.3
Unknown 13 21.7
Tumor grade I 14 23.3
II 23 38.3
III 16 26.7
Unknown 7 11.7
ER Negative 19 31.7
Positive 37 61.7
Unknown 4 6.7
PR Negative 36 60.0
Positive 21 35.0
Unknown 3 5.0
Her-2/neu Negative 31 51.7
Positive 21 35.0
Unknown 8 13.3
P53 Negative 41 68.3
Positive 15 25.0
Unknown 4 6.7
Race African American 15 25.0
Caucasian 44 73.3
Others 1 1.7
Age Minimum 40
Maximum 79
Average 59
Median 58.5BMC Cancer 2008, 8:136 http://www.biomedcentral.com/1471-2407/8/136
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diagnosed with DCIS ranged from 40 to 79 years with
58.5 years of age as the median.
Specificity of lectins used
We examined reactivity of these two lectins against an
array of carbohydrates by ELISA to confirm their binding
specificity (Figure 1). Both VVA and GS-I bind to terminal
α-GalNAc structures. VVA did bind to both α-GalNAc and
β-GalNAc but GS-I only reacted with α-GalNAc. GS-I
bound to Galα1-3Gal as expected, but it did not recognize
structures with terminal β-Gal such as the Thomsen-
Friedenreich (TF) antigen (Galβ1-3GalNAc attached to
proteins by an α O-serine or O-threonine linkage). Based
on this characterization, it appears that VVA binds to ter-
minal α- and β-GalNAc and GS-1 binds to terminal α-Gal-
and α-GalNAc-containing structures. These data confirm
that the Tn antigen, which resembles the O-glycan struc-
ture GalNAc-α 1-O-Ser/Thr can be recognized by both
lectins and may serve as an overlap target molecule in
staining with these two lectins.
Expression of VVA and GS-I-reactive epitopes in DCIS
We characterized the associations of GS-I and VVA reactiv-
ity with expression levels of ER, PR, p53 mutant, Her-2/
neu, and with age, race, tumor size and nuclear grade
(Table 2). Total number of specimens and specimens
from African American patients included in each analysis
is shown (Table 2). Both lectins showed significant asso-
ciations with nuclear grade of DCIS, with rank correla-
tions (MH P values) of 0.50 (0.0002) for GS-I and 0.48
(0.0005) for VVA. At 0.5% alpha, VVA showed a signifi-
cant correlation with Her2/Neu (rs  = 0.53; MH P  =
0.0004), but GS-1 did not (rs = 0.34; MH P = 0.015). Nei-
ther lectin showed significant correlations with tumor
size, ER, PR, or p53. Staining intensities for GS-I and VVA
were positively associated with each other (rs = 0.80; MH
P < 10-8), suggesting that in most cases the two lectins
either bind to a single structure, or to structures that some-
how are co-expressed.
We examined in more detail the nature of the lectin-stain-
ing associations with nuclear grade of DCIS (Figure 2).
GS-1 showed significantly more intense staining in
nuclear grades II and III compared to grade I (Mean-score
chi-square = 17.60, DF = 2; P = 0.0002), with average
staining-intensity scores (percents negatively stained) of
1.82+ (14%) in grade II and 2.00+ (0%) in grade III, com-
pared to 0.50+ (71%) in grade I (Figure 2A). VVA likewise
showed significantly more intense staining in nuclear
grades II and III compared to grade I (Mean-score chi-
square = 15.72, DF = 2; P = 0.0004), with average staining-
intensity scores (percents negatively stained) of 1.81+
(10%) in grade II and 1.94+ (0%) in grade III, compared
to 0.64+ (57%) in grade I (Figure 2B).
Results of lectin histochemical staining of a human breast
cancer cell line MDA-MB-231 and DCIS specimens are
demonstrated (Figure 3). Cytospin slides prepared from
MDA-MB-231 human breast cancer cell line were used to
set positive controls (Figure 3A). This tumor cell line
showed strong positivity with both GS-1 and VVA (Figure
3A). VVA and GS-I showed a similar level of intensity,
however a higher percentage of cells showed positivity
with GS-1 than with VVA. No reactivity was observed in
the absence of either lectin (Negative). We have shown
lectin binding to breast cancer cell lines by flow cytometry
[36,40,41]. Carbohydrate specificity of VVA and GS-I
lectins on paraffin-fixed breast cancer tissues has been
shown by others [29,42]. Lectin staining of normal sam-
ples and representative DCIS cases with various grades are
demonstrated (Figure 3B). Stromal cells show no staining
and the benign breast parenchyma shows only apical
staining with both GSI and VVL. Grade I DCIS cases,
Carbohydrate specificity of GS-I and VVA lectins Figure 1
Carbohydrate specificity of GS-I and VVA lectins. 
Reactivity of GS-I and VVA lectins with an array of carbohy-
drate probes was tested by a standard ELISA. Carbohydrate 
probes include: 1, GalNAcα 1→3GalNAcα-PAA; 2, 
Galβ1→4GlcNAcβ-PAA; 3, Galβ1→3GalNAcα-PAA; 4, 
GlcNAcβ1→3Galβ-PAA; 5, Galα1→3Galβ-PAA; 6, 
GlcNAcβ1→4GlcNAcβ-PAA; 7, β-GalNAc-PAA. The start-
ing concentration of each lectin was 10 μg/ml that was fur-
ther serially diluted. The assay was repeated three times with 
similar results. SD is shown for reactive sugars only.BMC Cancer 2008, 8:136 http://www.biomedcentral.com/1471-2407/8/136
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which were scored as negative predominantly showed api-
cal staining with minimal cytoplasmic staining, similar to
the pattern and level of staining within benign breast
parenchyma. This level of expression is considered nega-
tive. In grade I DCIS cases that were scored as positive, we
observed a diffuse cytoplasmic staining with both VVL
and GS1 clearly above the level of expression in normal
breast parenchyma. This pattern of staining was more sim-
ilar to the staining pattern seen in the high grade DCIS.
Grades II and III showed strong diffuse cytoplasmic stain-
ing. We also observed that a variation in the level of
expression existed within the neoplastic cells in high
grade DCIS.
Of the fourteen patients with grade-I DCIS, follow-up
information was available for 13. Further inspection of
the data revealed that five of the 13 showed recurrence in
the fourth, sixth, and seventh year of follow-up after their
original diagnosis. None of the 13 showed p53 or Her-2-
neu amplification, two of 13 were ER-negative and six of
13 were PR-negative. One of the13 patients died in the
third year of follow-up of an unrelated cause. The effect of
lectin positivity on RFS was examined using survival anal-
ysis. Figure 4A shows that 1 of 7 GS-1-negative subjects
had a recurrence in her 4th year of follow-up, while 4 of 6
GS-I-positive subjects had recurrences in their 6th and 7th
year of follow-up (log-rank P = 0.15). Figure 4B shows
that none of the 6 VVA-negative subjects had recurrences
during follow-up, whereas 5 of the 7 VVA-positive sub-
jects had recurrences in their 4th, 6th, and 7th year of fol-
low-up (log-rank P = 0.02). The effect on RFS of negativity
for ER or PR was examined, but was not significant
(results not shown).
Discussion
The belief that DCIS is a precursor of invasive breast can-
cer necessitates the search for finding specific DCIS-asso-
ciated antigens to identify patients at greater risk for
development of invasive cancer and recurrence. Many
studies have examined molecular markers in DCIS that
are used in clinical practice for invasive breast cancer [43-
51]. An overall similarity is reported in the expression of
these markers in DCIS and invasive cancer, but with no
definite conclusion as to the relevance of these markers to
tumor invasion, recurrence and progression.
To search for possible DCIS-associated molecular markers
that recognize high-risk DCIS patients, we performed a
lectin histochemical staining focusing on breast-cancer-
relevant TACAs and evaluated their correlations with
tumor prognostic factors. We observed positive correla-
tions between the expression of VVA- and GS-I-reactive
structures and tumor grade in DCIS patients. Because
tumor grade is the most relevant pathologic determinant
of disease with invasive potential, these data suggest that
glycoconjugates containing these antigens are associated
with invasiveness in DCIS. Tumor grade has been shown
to predict prognosis using four gene-expression-based
models (70-gene, wound response, two-gene ratio, and
recurrence score) [52] and has been used as a major com-
ponent in prognostic classification of DCIS [11,17,18].
The statistically significant positive correlations observed
between the grade of DCIS and the expression of struc-
tures reactive with GS-1 and VVA suggest that these reac-
tive antigens may define a phenotype for disease
progression or DCIS transformation to invasive disease.
Lack of association of reactivity of either lectin with age
and race indicates that reactive structures are independent
Table 2: Correlation between prognostic markers, race, age, tumor grade and tumor size with GS-I and VVA expression levels IN 
DCIS patients
GS-I VVA
corra MH χ2b MH Pb Nctotal NcAA corra MH χ2b MH Pb Nctotal NcAA
Tumor grade 0.50 14.04 0.0002 51 12 0.48 12.31 0.0005 51 13
Tumor size 0.04 0.29 0.59 44 9 0.01 0.10 0.76 45 11
ER -.19 2.22 0.14 52 12 -.26 3.92 0.048 52 14
PR -.21 3.44 0.064 51 11 -.20 3.80 0.051 50 13
p53 0.29 3.13 0.077 49 12 0.25 2.23 0.14 48 14
Her-2/neu 0.34 5.98 0.015 49 11 0.53 12.75 0.0004 48 13
Age 0.05 --- 0.72d 56 12 -.04 --- 0.75d 55 14
Race 0.06 0.08 0.78 55 12 -.16 1.53 0.22 54 14
a: Spearman's coefficient of rank correlation with lectin staining-intensity score.
b: Chi-square statistic and P value, Mantel-Haenszel (MH) test for correlation between ordinal categorical variables. P values shown in bold face are 
statistically significant at 0.5% alpha.
c: Number non-missing. Total is total non-missing; AA is non-missing African-Americans.
d: P value for rank correlation of Age (continuous variable) with lectin staining-intensity score.BMC Cancer 2008, 8:136 http://www.biomedcentral.com/1471-2407/8/136
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of race and age. Together, these data suggest that histolog-
ical evaluation of the expression of VVA- and GS-I-reactive
TACAs may serve as phenotypic markers of not only high
grade DCIS as defined by nuclear grade, but they may also
define DCIS cases which are at high risk for recurrence. In
support of this conjecture is the observation that of a total
of 13 Low-grade (grade I) DCIS cases in our study, only
seven were found positive for VVA lectin and interestingly
five of these seven cases were diagnosed with recurrences
later in their life. The data suggest that the expression of
the lectin-reactive structures in DCIS may play a role in
tumor relapse. Further studies targeting low-grade DCIS
specimens are needed to make conclusive remarks.
The exact nature of reactive carbohydrates in our staining
with VVA and GS-I lectins is not known. Our data con-
firms the specificity of both lectins. We observed that VVA
binds to both α-GalNAc and β-GalNAc, which is consist-
ent with data published by others [30]. Specificity of GS-I
to α-GalNAc and α-Gal structures is also reported in the
literature [33-35,53,54]. However, the α-Gal epitope is
supposed to be absent in humans, because of a lack of
alpha1,3-galactosyltransferase activity [55,56]. Therefore,
the overall correlative nature, observed in this study,
between staining of these two lectins suggests that they
Lectin histochemical staining of MDA-MB-231 breast cancer  cell line and ductal carcinoma in situ Figure 3
Lectin histochemical staining of MDA-MB-231 breast 
cancer cell line and ductal carcinoma in situ.A) Cyt-
ospin slides of MDA-MB-231 cells, which were grown in vitro 
and harvested using enzyme-free buffer. The negative control 
and staining with GS-I and VVA are shown. MDA-MB-231 
breast cancer cell line shows cytoplasmic staining with both 
lectins and did not show any staining in the absence of the 
lectins (Negative). 40× Magnification. B) Staining of normal 
breast tissues and tumor samples of different nuclear grade 
with VVA and GS-I lectins. 20× magnification, bar equals 50 
μm.
Distribution of lectin staining intensity among DCIS speci- mens with low (grade I), intermediate (grade II) and high  (grade III) nuclear grade Figure 2
Distribution of lectin staining intensity among DCIS 
specimens with low (grade I), intermediate (grade II) 
and high (grade III) nuclear grade. Vertical axes show 
DCIS grade. Numbers inside stacked bars show number of 
patients with each level of staining intensity while the hori-
zontal axes show the patient numbers as proportions of total 
patients per grade. For each grade, the average staining-
intensity score was calculated as: 0 × (proportion neg) + 1 × 
(proportion 1+) + 2 × (proportion 2+) + 3 × (proportion 
3+). A) shows that average staining intensity for Griffonia sim-
plicifolia lectin-I (GS-I) was significantly higher in grades II and 
III than in grade I (Mean-score chi-square = 17.60, DF = 2; P 
= 0.0002). B) shows that average staining intensity for Vicia 
vilosa agglutinin (VVA) was significantly higher in grades II and 
III than in grade I (Mean-score chi-square = 15.72, DF = 2; P 
= 0.0004).BMC Cancer 2008, 8:136 http://www.biomedcentral.com/1471-2407/8/136
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both may react with a single epitope on potentially many
antigens. Consistently, our data indicate that the Tn anti-
gen (α-GalNAc, an O-linked carbohydrate structure) is an
overlapping epitope reactive with these two lectins. How-
ever, the fact that, at 0.5% alpha, VVA showed a significant
correlation with Her-2/Neu, but GS-I did not, suggests
that there may be a distinct nature of reactivity for these
two lectins on breast cancer specimens. This data also sug-
gests that Her-2/neu protein might be decorated predom-
inantly with β-GalNAc-containing sugar chains rather
than structures that contain α-GalNAc. In this regard,
while VVA targets mostly O-linked carbohydrates, binding
of GS-I lectin to human breast carcinomas may be related
to other unknown antigens. Other investigators also
reported the reactivity of α-Gal-specifc GS-I-B4 isolectin
with human breast cancer tissues [22,42], which suggests
that even if there is no α-Gal expression, another reactive
structure should exist on human tumors. Ito and cowork-
ers [42], proposed that poly-N-acetyllactosamines of N-
linked glycans contain GS-I-B4 specific epitope on human
breast cancer cells. Obviously, the identity of GS-I reactive
structures on human breast cancer cells is not clear at the
present time and further efforts are needed to identify
these antigens.
Conclusion
Our results suggest that the expression of VVA- and GS-I-
reactive carbohydrate antigens may contribute to forming
higher grade DCIS and increase the recurrence risk. Such
carbohydrates might ultimately serve as viable targets for
future development of novel therapeutic strategies aiming
at early stage of breast cancer. However, the elucidation of
their role in biology and patho-physiology of the disease,
which needs further research, precedes such efforts. The
data also support the hypothesis of using the expression
of these structures as prognostic markers for early stage
breast cancer that necessitate conducting further studies
on much larger sample size of low-grade DCIS specimens
with long follow-up time to establish whether low-grade
DCIS with a specific glycomic profile can be subject to
relapse more often than other tumors of the same cate-
gory.
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